A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults With Stargardt Disease Related Atrophy Secondary to Biallelic Mutations in the ABCA4 Gene

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease progression, and to further characterize the patient population for future clinical studies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Maximum Age: 50
Healthy Volunteers: f
View:

• Male and female subjects between 8 and 50 years of age at the time of enrolment.

• Willingness to adhere to the protocol as evidenced by written informed consent if the subject is 18 years or older. If the subject is under 18 years of age, written assent must be obtained from the subject and written informed consent must be obtained from the subject's legally authorized representative (parent or legal guardian).

• Confirmed mutation in the ABCA4 gene.

Locations
United States
Texas
Retina Foundation of the Southwest
RECRUITING
Dallas
Other Locations
Norway
Oslo University hospital Ullevål
RECRUITING
Oslo
Contact Information
Primary
Clinical Operations Manager
clinicaltrials@aavantgarde.com
+44 (0) 800 046 5680
Time Frame
Start Date: 2024-05-01
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 80
Related Therapeutic Areas
Sponsors
Leads: AAVantgarde Bio Srl

This content was sourced from clinicaltrials.gov

Similar Clinical Trials